BioCentury | Sep 15, 2017
Clinical News

Amicus' SD-101 misses in Phase III for skin blistering disorder

...in the U.S. and EU for EB. Amicus gained SD-101 through its 2015 acquisition of Scioderm Inc....
BioCentury | Sep 13, 2017
Clinical News

Amicus' SD-101 misses in Phase III for skin blistering disorder

...in the U.S. and EU for EB. Amicus gained SD-101 through its 2015 acquisition of Scioderm Inc....
BioCentury | Jun 9, 2017
Clinical News

Amicus receives rare pediatric disease designation for EB candidate SD-101

...designation in the U.S. and EU. Amicus acquired the product through its 2015 acquisition of Scioderm Inc....
BioCentury | Mar 19, 2016
Company News

Management tracks

...CFO. Shalwitz was co-founder and CMO at Akebia Therapeutics Inc. (NASDAQ:AKBA). Howes was CFO at Scioderm Inc....
BioCentury | Jan 1, 2016
Company News

Management tracks

...Robert Ryan stepped down as CEO of Scioderm Inc. (Raleigh, N.C.). Amicus Therapeutics Inc. (NASDAQ:FOLD) acquired the...
BioCentury | Oct 26, 2015
Company News

Scioderm, Amicus Therapeutics deal

...completed its acquisition of Scioderm for $136 million in cash and $84 million Amicus shares. Scioderm...
...SD-101 ), an undisclosed topical cream in Phase III testing to treat epidermolysis bullosa. Scioderm...
...of Zorblisa if a Priority Review voucher is obtained and sold (see BioCentury, Sept. 7). Scioderm...
BioCentury | Sep 7, 2015
Company News

Scioderm, Amicus Therapeutics deal

...Amicus will acquire Scioderm for $125 million in cash and $104 million in stock up front...
...part of the submission. If the company obtains and subsequently sells a Priority Review voucher, Scioderm...
...human acid alpha-glucosidase ( rhGAA ). The parties expect the deal to close this quarter. Scioderm...
BioCentury | Sep 1, 2015
Company News

Amicus to acquire Scioderm

...Amicus Therapeutics Inc. (NASDAQ:FOLD) will acquire Scioderm LLC (Raleigh, N.C.), giving it Zorblisa ( SD-101...
...SD-005 trial of the compound, and hopes to begin a rolling NDA submission in 4Q15. Scioderm...
...Priority Review voucher program. If the company obtains and subsequently sells a Priority Review voucher, Scioderm...
BioCentury | Aug 17, 2015
Clinical News

Zorblisa regulatory update

...in the U.S. and Orphan Drug designation in the U.S. and EU for the indication. Scioderm...
BioCentury | Mar 30, 2015
Clinical News

Zorblisa: Phase III started

...Patients completing SD-005 may enroll in the open-label SD-006 extension study to assess long-term safety. Scioderm...
Items per page:
1 - 10 of 21
BioCentury | Sep 15, 2017
Clinical News

Amicus' SD-101 misses in Phase III for skin blistering disorder

...in the U.S. and EU for EB. Amicus gained SD-101 through its 2015 acquisition of Scioderm Inc....
BioCentury | Sep 13, 2017
Clinical News

Amicus' SD-101 misses in Phase III for skin blistering disorder

...in the U.S. and EU for EB. Amicus gained SD-101 through its 2015 acquisition of Scioderm Inc....
BioCentury | Jun 9, 2017
Clinical News

Amicus receives rare pediatric disease designation for EB candidate SD-101

...designation in the U.S. and EU. Amicus acquired the product through its 2015 acquisition of Scioderm Inc....
BioCentury | Mar 19, 2016
Company News

Management tracks

...CFO. Shalwitz was co-founder and CMO at Akebia Therapeutics Inc. (NASDAQ:AKBA). Howes was CFO at Scioderm Inc....
BioCentury | Jan 1, 2016
Company News

Management tracks

...Robert Ryan stepped down as CEO of Scioderm Inc. (Raleigh, N.C.). Amicus Therapeutics Inc. (NASDAQ:FOLD) acquired the...
BioCentury | Oct 26, 2015
Company News

Scioderm, Amicus Therapeutics deal

...completed its acquisition of Scioderm for $136 million in cash and $84 million Amicus shares. Scioderm...
...SD-101 ), an undisclosed topical cream in Phase III testing to treat epidermolysis bullosa. Scioderm...
...of Zorblisa if a Priority Review voucher is obtained and sold (see BioCentury, Sept. 7). Scioderm...
BioCentury | Sep 7, 2015
Company News

Scioderm, Amicus Therapeutics deal

...Amicus will acquire Scioderm for $125 million in cash and $104 million in stock up front...
...part of the submission. If the company obtains and subsequently sells a Priority Review voucher, Scioderm...
...human acid alpha-glucosidase ( rhGAA ). The parties expect the deal to close this quarter. Scioderm...
BioCentury | Sep 1, 2015
Company News

Amicus to acquire Scioderm

...Amicus Therapeutics Inc. (NASDAQ:FOLD) will acquire Scioderm LLC (Raleigh, N.C.), giving it Zorblisa ( SD-101...
...SD-005 trial of the compound, and hopes to begin a rolling NDA submission in 4Q15. Scioderm...
...Priority Review voucher program. If the company obtains and subsequently sells a Priority Review voucher, Scioderm...
BioCentury | Aug 17, 2015
Clinical News

Zorblisa regulatory update

...in the U.S. and Orphan Drug designation in the U.S. and EU for the indication. Scioderm...
BioCentury | Mar 30, 2015
Clinical News

Zorblisa: Phase III started

...Patients completing SD-005 may enroll in the open-label SD-006 extension study to assess long-term safety. Scioderm...
Items per page:
1 - 10 of 21